Near-patient testing of natriuretic peptides;Patientennahe Bestimmung natriuretischer Peptide

LaboratoriumsMedizin

Volumn 29, Issue 4, 2005, Pages 219-228

  Peetz, Dirk ^a   Hafner, Gerd ^b   Lackner, Karl J ^a  

^a UNIVERSITY MEDICAL CENTER MAINZ   (Germany)

^b Zentrum Für Labordiagnostik und Mikrobiologie   (Germany)

Author keywords

Bedside testing; Brain natriuretic peptides; Point of care systems; Pro brain natriuretic peptide (1 76)

Indexed keywords

BRAIN NATRIURETIC PEPTIDE; NATRIURETIC FACTOR;

ACUTE HEART INFARCTION; DYSPNEA; ECONOMIC ASPECT; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART VENTRICLE HYPERTROPHY; HUMAN; PATHOPHYSIOLOGY; REVIEW; VALVULAR HEART DISEASE;

EID: 24044462127     PISSN: 03423026     EISSN: None     Source Type: Journal    
DOI: 10.1515/JLM.2005.030     Document Type: Review

References (74)

1. Cowie MR, Mosterd A, Wood DA, Deckers JW, Poole-Wilson PA, Sutton GC, et al. The epidemiology of heart failure. Eur Heart J 1997;18:208-25.
2. Cowie MR, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, Suresh V, et al. Incidence and aetiology of heart failure; a population-based study. Eur Heart J 1999;20:421-8.
3. Jessup M, Brozena S. Heart failure. N Engl J Med 2003;348:2007-18.
4. Polanczyk CA, Rohde LE, Dec GW, DiSalvo T. Ten-year trends in hospital care for congestive heart failure: improved outcomes and increased use of resources. Arch Intern Med 2000;160:325-32.
5. Remme WJ, Swedberg K. Guidelines for the diagnosis and treatment of chronic heart failure. Eur Heart J 2001;22:1527-60.
6. Maisel AS. The diagnosis of acute congestive heart failure: role of BNP measurements. Heart Fail Rev 2003;8:327-34.
7. Maisel AS, Koon J, Krishnaswamy P, Kazenegra R, Clopton P, Gardetto N, et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. Am Heart J 2001;141:367-74.
8. Dao Q, Krishnaswamy P, Kazanegra R, Harrison A, Amirnovin R, Lenert L, et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgentcare setting. J Am Coll Cardiol 2001;37:379-85.
9. Boomsma F, van den Meiracker AH. Plasma A- and B-type natriuretic peptides: physiology, methodology and clinical use. Cardiovasc Res 2001;51:442-9.
10. Maeda K, Tsutamoto T, Wada A, Hisanaga T, Kinoshita M. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998;135:825-32.
11. de Bold AJ, Ma KK, Zhang Y, de Bold ML, Bensimon M, Khoshbaten A. The physiological and pathophysiological modulation of the endocrine function of the heart. Can J Physiol Pharmacol 2001;79:705-14.
12. Christoffersen C, Goetze JP, Bartels ED, Larsen MO, Ribel U, Rehfeld JF, et al. Chamber-dependent expression of brain natriuretic peptide and its mRNA in normal and diabetic pig heart. Hypertension 2002;40:54-60.
13. Clerico A, Iervasi G, Mariani G. Pathophysiologic relevance of measuring the plasma levels of cardiac natriuretic peptide hormones in humans. Horm Metab Res 1999;31:487-98.
14. Mukoyama M, Nakao K, Hosoda K, Suga S, Saito Y, Ogawa Y, et al. Brain natriuretic peptide as a novel cardiac hormone in humans. Evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991;87:1402-12.
15. Mair J, Hammerer-Lercher A, Puschendorf B. The impact of cardiac natriuretic peptide determination on the diagnosis and management of heart failure. Clin Chem Lab Med 2001;39:571-88.
16. Cowie MR, Struthers AD, Wood DA, Coats AJ, Thompson SG, Poole-Wilson PA, et al. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1997;350:1349-53.
17. Wu F, Yan W, Pan J, Morser J, Wu Q. Processing of pro-atrial natriuretic peptide by corin in cardiac myocytes. J Biol Chem 2002;277:16900-5.
18. Hunt PJ, Espiner EA, Nicholls MG, Richards AM, Yandle TG. The role of the circulation in processing pro-brain natriuretic peptide (proBNP) to amino-terminal BNP and BNP-32. Peptides 1997;18:1475-81.
19. Kalra PR, Clague JR, Bolger AP, Anker SD, Poole-Wilson PA, Struthers AD, et al. Myocardial production of C-type natriuretic peptide in chronic heart failure. Circulation 2003;107:571-3.
20. Kinugawa T, Kato M, Ogino K, Osaki S, Igawa O, Hisatome I, et al. Plasma endothelin-1 levels and clinical correlates in patients with chronic heart failure. J Card Fail 2003;9:318-24.
21. Horwich TB, Patel J, MacLellan WR, Fonarow GC. Cardiac troponin I is associated with impaired hemodynamics, progressive left ventricular dysfunction, and increased mortality rates in advanced heart failure. Circulation 2003;108:833-8.
22. Berton G, Cordiano R, Palmieri R, Pianca S, Pagliara V, Palatini P. C-reactive protein in acute myocardial infarction: association with heart failure. Am Heart J 2003;145:1094-101.
23. Alonso-Martinez JL, Llorente-Diez B, Echegaray-Agara M, Olaz-Preciado F, Urbieta-Echezarreta M, Gonzalez-Arencibia C. C-reactive protein as a predictor of improvement and readmission in heart failure. Eur J Heart Fail 2002;4:331-6.
24. Chen MM, Ashley EA, Deng DX, Tsalenko A, Deng A, Tabibiazar R, et al. Novel role for the potent endogenous inotrope apelin in human cardiac dysfunction. Circulation 2003;108:1432-9.
25. Foldes G, Horkay F, Szokodi I, Vuolteenaho O, Ilves M, Lindstedt KA, et al. Circulating and cardiac levels of apelin, the novel ligand of the orphan receptor APJ, in patients with heart failure. Biochem Biophys Res Commun 2003;308:480-5.
26. O'Brien RJ, Loke I, Davies JE, Squire IB, Ng LL. Myotrophin in human heart failure. J Am Coll Cardiol 2003;42:719-25.
27. Ng LL, Loke I, O'Brien RJ, Squire IB, Davies JE. Plasma urotensin in human systolic heart failure. Circulation 2002;106:2877-80.
28. Richards AM, Doughty R, Nicholls MG, MacMahon S, Sharpe N, Murphy J, et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction. Australia-New Zealand Heart Failure Group. J Am Coll Cardiol 2001;37:1781-7.
29. Talwar S, Squire IB, Downie PF, O'Brien RJ, Davies JE, Ng LL. Elevated circulating cardiotrophin-1 in heart failure: relationship with parameters of left ventricular systolic dysfunction. Clin Sci (Lond) 2000;99:83-8.
30. Silver MA, Maisel A, Yancy CW, McCullough PA, Burnett JC Jr, Francis GS, et al. BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Congest Heart Fail 2004;10(5 Suppl 3):1-30.
31. Doust JA, Glasziou PP, Pietrzak E, Dobson AJ. A systematic review of the diagnostic accuracy of natriuretic peptides for heart failure. Arch Intern Med 2004;164:1978-84.
32. Cowie MR, Mendez GF. BNP and congestive heart failure. Prog Cardiovasc Dis 2002;44:293-321.
33. Brunner-La Rocca HP, Kiowski W, Ramsay D, Sutsch G. Therapeutic benefits of increasing natriuretic peptide levels. Cardiovasc Res 2001;51:510-20.
34. Struthers AD. Introducing a new role for BNP: as a general indicator of cardiac structural disease rather than a specific indicator of systolic dysfunction only. Heart 2002;87:97-8.
35. Maisel A. B-type natriuretic peptide levels: a potential novel "white count" for congestive heart failure. J Card Fail 2001;7:183-93.
36. Tang WHW. NACB: Recommendations for the use of Cardiac Biomarkers in Heart Failure. Second Draft: February 27, 2004. http://www.nacb.org/lmpg/ biomark/card_biomarkers_chp2.pdf
37. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, et al. N-terminal pro-brain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease: a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy. Circulation 2003;108:275-81.
38. Richards AM, Nicholls MG, Espiner EA, Lainchbury JG, Troughton RW, Elliott J, et al. B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation 2003;107:2786-92.
39. Omland T, Persson A, Ng L, O'Brien R, Karlsson T, Herlitz J, et al. N-terminal pro-B-type natriuretic peptide and longterm mortality in acute coronary syndromes. Circulation 2002;106:2913-8.
40. de Lemos JA, Morrow DA. Combining natriuretic peptides and necrosis markers in the assessment of acute coronary syndromes. Rev Cardiovasc Med 2003;4 Suppl 4:S37-46.
41. Schnabel R, Rupprecht HJ, Lackner KJ, Lubos E, Bickel C, Meyer J, et al. Analysis of N-terminal-pro-brain natriuretic peptide and C-reactive protein for risk stratification in stable and unstable coronary artery disease: results from the AtheroGene study. Eur Heart J 2005;26:241-9.
42. Cheng V, Kazanagra R, Garcia A, Lenert L, Krishnaswamy P, Gardetto N, et al. A rapid bedside test for B-type peptide predicts treatment outcomes in patients admitted for decompensated heart failure: a pilot study. J Am Coll Cardiol 2001;37:386-91.
43. Anand IS, Fisher LD, Chiang YT, Latini R, Masson S, Maggioni AP, et al. Changes in brain natriuretic peptide and norepinephrine over time and mortality and morbidity in the Valsartan Heart Failure Trial (Val-HeFT). Circulation 2003;107:1278-83.
44. Gardner RS, Ozalp F, Murday AJ, Robb SD, McDonagh TA. N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure. Eur Heart J 2003;24:1735-43.
45. Koglin J, Pehlivanli S, Schwaiblmair M, Vogeser M, Cremer P, Von Scheidt W. Clinical value of brain natriuretic peptide for candidate selection before cardiac transplantation. J Heart Lung Transplant 2001;20:164.
46. Pruszczyk P, Kostrubiec M, Bochowicz A, Styczynski G, Szulc M, Kurzyna M, et al. N-terminal pro-brain natriuretic peptide in patients with acute pulmonary embolism. Eur Respir J 2003;22:649-53.
47. Kruger S, Graf J, Merx MW, Koch KC, Kunz D, Hanrath P, et al. Brain natriuretic peptide predicts right heart failure in patients with acute pulmonary embolism. Am Heart J 2004;147:60-5.
48. Troughton RW, Frampton CM, Yandle TG, Espiner EA, Nicholls MG, Richards AM. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (NBNP) concentrations. Lancet 2000;355:1126-30.
49. Shimizu H, Masuta K, Asada H, Sugita K, Sairenji T. Characterization of molecular forms of pro-brain natriuretic peptide in human plasma. Clin Chim Acta 2003;334:233-9.
50. Shimizu H, Aono K, Masuta K, Asada H, Misaki A, Teraoka H. Degradation of human brain natriuretic peptide (BNP) by contact activation of blood coagulation system. Clin Chim Acta 2001;305:181-6.
51. Gobinet-Georges A, Valli N, Filliatre H, Dubernet MF, Dedeystere O, Bordenave L. Stability of brain natriuretic peptide (BNP) in human whole blood and plasma. Clin Chem Lab Med 2000;38:519-23.
52. Goetze JP, Kastrup J, Pedersen F, Rehfeld JF. Quantification of pro-B-type natriuretic peptide and its products in human plasma by use of an analysis independent of precursor processing. Clin Chem 2002;48:1035-42.
53. Hall C. Essential biochemistry and physiology of (NT-pro) BNP. Eur J Heart Fail 2004;6:257-60.
54. Ala-Kopsala M, Magga J, Peuhkurinen K, Leipala J, Ruskoaho H, Leppaluoto J, et al. Molecular heterogeneity has a major impact on the measurement of circulating N-terminal fragments of A- and B-type natriuretic peptides. Clin Chem 2004;50:1576-88.
55. Schulz H, Langvik TA, Lund Sagen E, Smith J, Ahmadi N, Hall C. Radioimmunoassay for N-terminal pro-brain natriuretic peptide in human plasma. Scand J Clin Lab Invest 2001;61:33-42.
56. Seidler T, Pemberton C, Yandle T, Espiner E, Nicholls G, Richards M. The amino terminal regions of proBNP and proANP oligomerise through leucine zipper-like coiledcoil motifs. Biochem Biophys Res Commun 1999;255:495-501.
57. Nowatzke WL, Cole TG. Stability of N-terminal pro-brain natriuretic peptide after storage frozen for one year and after multiple freeze-thaw cycles. Clin Chem 2003;49:1560-2.
58. Hafner G, Peetz D, Dati F. Patientennahe Bestimmung der Troponine zur Diagnostik akuter Koronarsyndrome. Laboratoriums Medizin 2003;27:279-87.
59. Panteghini M, Apple FS, Christenson RH, Dati F, Mair J, Wu AH. Use of biochemical markers in acute coronary syndromes. IFCC Scientific Division, Committee on Standardization of Markers of Cardiac Damage. International Federation of Clinical Chemistry. Clin Chem Lab Med 1999;37:687-93.
60. Storrow AB. NACB: Laboratory Guidelines for Evidence-Based Practice for POCT. NACB Recommendations - Logistics (Administrative, Cost-effectiveness, Point-of-care, what are the rules?). Draft: March 29, 2004. http://www.nacb.org/ lmpg/poct/chp3_cardiac.pdf
61. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999;34:890-911.
62. Rusnak RA, Stair TO, Hansen K, Fastow JS. Litigation against the emergency physician: common features in cases of missed myocardial infarction. Ann Emerg Med 1989;18:1029-34.
63. Tierney WM, Fitzgerald J, McHenry R, Roth BJ, Psaty B, Stump DL, et al. Physicians' estimates of the probability of myocardial infarction in emergency room patients with chest pain. Med Decis Making 1986;6:12-7.
64. Mueller C, Scholer A, Laule-Kilian K, Martina B, Schindler C, Buser P, et al. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N Engl J Med 2004;350:647-54.
65. Richtlinie der Bundesärztekammer zur Qualitätssicherung quantitativer laboratoriumsmedizinischer Untersuchungen (gültig ab 01.01.2002). Stand: 18.04.2005. http://www.bundesaerztekammer.de/30/Richtlinien/ Richtidx/Labor2002/RiliLabor.pdf
66. Jacobs E, Goldsmith B, Larrson L, Richardson H, St. Louis P. NACB Laboratory Medicine Practice Guidelines Evidence-Based Practice for Point of Care Testing Introduction/Management. Stand: 18.04.2005. http://www.nacb.org/ lmpg/poct/chp1_intro.pdf
67. Kost GJ. Preventing medical errors in point-of-care testing: security, validation, safeguards, and connectivity. Arch Pathol Lab Med 2001;125:1307-15.
68. Nichols JH. Quality in point-of-care testing. Expert Rev Mol Diagn 2003;3:563-72.
69. Jansen RT, Blaton V, Burnett D, Huisman W, Queralto JM, Zerah S, et al. Essential criteria for quality systems in medical laboratories. Eur J Clin Chem Clin Biochem 1997;35:121-2.
70. Rich MW. Epidemiology, pathophysiology, and etiology of congestive heart failure in older adults. J Am Geriatr Soc 1997;45:968-74.
71. Krumholz HM, Wang Y, Parent EM, Mockalis J, Petrillo M, Radford MJ. Quality of care for elderly patients hospitalized with heart failure. Arch Intern Med 1997;157:2242-7.
72. Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, et al. Plasma norepinephrine as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 1984;311:819-23.
73. McCullough PA, Sandberg KR. Sorting out the evidence on natriuretic peptides. Rev Cardiovasc Med 2003;4 Suppl 4:S13-9.
74. Apple FS, Panteghini M, Ravkilde J, Mair J, Wu AH, Tate J, et al. Quality specifications for B-type natriuretic peptide assays. Clin Chem 2005;51:486-93.